Close
Help




JOURNAL

Clinical Medicine Insights: Pediatrics

156,440 Journal Article Views | Journal Analytics

Efficacy and Tolerability of Pharmacotherapy Options for the Treatment of Irritability in Autistic Children

Submit a Paper



Publication Date: 25 May 2014

Type: Review

Journal: Clinical Medicine Insights: Pediatrics

Citation: Clinical Medicine Insights: Pediatrics 2014:8 17-30

doi: 10.4137/CMPed.S8304

Abstract

Children with autism have a high rate of irritability and aggressive symptoms. Irritability or self-injurious behavior can result in significant harm to those affected, as well as to marked distress for their families. This paper provides a literature review regarding the efficacy and tolerability of pharmacotherapy for the treatment of irritability in autistic children. Although antipsychotics have not yet been approved for the treatment of autistic children by many countries, they are often used to reduce symptoms of behavioral problems, including irritability, aggression, hyperactivity, and panic. However, among antipsychotics, the Food and Drug Administration has approved only risperidone and aripiprazole to treat irritability in autism. Among atypical antipsychotics, olanzapine and quetiapine are limited in their use for autism spectrum disorders in children because of high incidences of weight gain and sedation. In comparison, aripiprazole and ziprasidone cause less weight gain and sedation. However, potential QTc interval prolongation with ziprasidone has been reported. Contrary to ziprasidone, no changes were evident in the QT interval in any of the trials for aripiprazole. However, head-to-head comparison studies are needed to support that aripiprazole may be a promising drug that can be used to treat irritability in autistic children. On the other hand, risperidone has the greatest amount of evidence supporting it, including randomized controlled trials; thus, its efficacy and tolerability has been established in comparison with other agents. Further studies with risperidone as a control drug are needed.


Downloads

PDF  (636.45 KB PDF FORMAT)

RIS citation   (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)

BibTex citation   (BIBDESK, LATEX)

XML






What Your Colleagues Say About Clinical Medicine Insights: Pediatrics
The publishing experience in Libertas Academica journals is unique. Readers can feel satisfied that publications are peer reviewed. Authors follow simple steps to reach final stage of publication. All readers have access to articles. Journal subscriptions or medical library access is not needed.
Dr Akram Al Hilali (Consultant Hematopathologist, Dubai Health Authority, Dubai)
More Testimonials

Quick Links


New article and journal news notification services